Squamous cell carcinoma of the head and neck: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Open Access
- 1 May 2009
- journal article
- review article
- Published by Elsevier BV in Annals of Oncology
- Vol. 20 (suppl_4), iv121-iv122
- https://doi.org/10.1093/annonc/mdp149
Abstract
In 2002, the crude incidence rates of Squamous cell carcinoma of the head and neck (SCCHN) in Europe were 36/100 000/year in the male population and 7/100 000/year for females, while the corresponding mortality rates were 18 and 3/100 000/year.This publication has 10 references indexed in Scilit:
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerThe New England Journal of Medicine, 2008
- Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck CancerThe New England Journal of Medicine, 2007
- Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck CancerThe New England Journal of Medicine, 2007
- Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): An UpdateInternational Journal of Radiation Oncology*Biology*Physics, 2007
- Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and NeckThe New England Journal of Medicine, 2006
- Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck CancerJournal of Clinical Oncology, 2005
- Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and NeckThe New England Journal of Medicine, 2004
- Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck CancerThe New England Journal of Medicine, 2004
- Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal CancerThe New England Journal of Medicine, 2003
- Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.Journal of Clinical Oncology, 1992